Mineralys Therapeutics Raises $650M+ in Capital Blitz to Clear Path for Lorundrostat Launch

Mineralys raised cash via $150M stock sale, $500M loan, and $200M royalty buyout to fund drug ahead of FDA decision; stock fell.